The Helmholtz Zentrum München is one of 15 national laboratories in Germany joint within the Helmholtz Association (former GSF). Within this association the Helmholtz Zentrum München competes with 3 other national laboratories for the budget allocated to the research field of “Health”. The annual budget of the Helmholtz Association comes 90% from the Federal Government of Germany and 10% from the States of Germany. There are about 1800 employees within the Helmholtz Zentrum München; annual budget is about 220 Mio€. Its mission is the improvement of human health being based on a better understanding of human health and the environment.
The Institute for Inhalation Biology focuses on health risks associated with exposure to airborne stressors and their potential role in lung diseases. In particular, the relevance of combustion-derived ultrafine particles (< 0.1 μm diameter) and manufactured nanomaterials are major concerns. The aerosol research covers dosimetric aspects of exposure, but also the use of particles for the early detection of lung disease. HZMU is interested in the dosimetry of incorporated Nanoparticles and the responses of the various biological systems.
Activities in the project
HMGU will be involved in all the in vivo experiments that aim at validating the InLiveTox system. HMGU will perform quantitative biokinetics using radio-labelled NP on healthy rats and on rats with an inflamed intestine.
Expertise in these activities / Previous experiences
Over the last ten years HMGU have developed the technology of quantitative biokinetics of incorporated radio-labelled nanoparticles which allows them to determine the biodistribution of nanoparticles in the whole organism of rodents over four orders of magnitude.
Key people involved
Prof. Wolfgang G. Kreyling is at HMGU since 1973. He is currently deputy director of Institute of Inhalation Biology and Coordinator of Focus Network Nanoparticles ad Health. He has more than 30 years of experience in aerosol science, inhalation exposure, interaction and dosimetry of particles with the respiratory tract and the entire organism (from man to mouse) andhe is working since ten years in nanoparticles. He has been involved in EU projects in FP4, FP5, FP6 and FP7.
Some relevant publications / Patent